I can only thing there is a bigger play here because the deal on the surface makes no sense when you consider Avant's diagnostic test is more than a year away from FDA approval, assuming it gets approved. The only thing I can think of is that OVADX will be paired with AMBS' diagnostic tests and the company sold with all assets. Regardless, Gerald has once again undermined his investors and has yet to explain what is going on. Par for the course for him.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links